ProfileGDS4814 / ILMN_1669070
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 86% 86% 86% 86% 87% 87% 86% 86% 86% 86% 87% 87% 85% 86% 88% 87% 87% 86% 88% 87% 87% 86% 87% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)256.62186
GSM780708Untreated after 4 days (C2_1)259.62386
GSM780709Untreated after 4 days (C3_1)267.86686
GSM780719Untreated after 4 days (C1_2)251.83286
GSM780720Untreated after 4 days (C2_2)287.1787
GSM780721Untreated after 4 days (C3_2)275.27387
GSM780710Trastuzumab treated after 4 days (T1_1)260.87586
GSM780711Trastuzumab treated after 4 days (T2_1)255.64786
GSM780712Trastuzumab treated after 4 days (T3_1)249.12186
GSM780722Trastuzumab treated after 4 days (T1_2)266.89186
GSM780723Trastuzumab treated after 4 days (T2_2)279.29787
GSM780724Trastuzumab treated after 4 days (T3_2)282.47787
GSM780713Pertuzumab treated after 4 days (P1_1)240.27385
GSM780714Pertuzumab treated after 4 days (P2_1)259.92886
GSM780715Pertuzumab treated after 4 days (P3_1)304.09288
GSM780725Pertuzumab treated after 4 days (P1_2)280.60387
GSM780726Pertuzumab treated after 4 days (P2_2)278.20787
GSM780727Pertuzumab treated after 4 days (P3_2)254.49486
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)309.52688
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)277.67787
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)300.86187
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)269.79586
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)298.14687